Session 26 - CROI 2007

Session 26 Oral Abstracts
New Antiretroviral Agents, Resistance Mechanisms, and Clinical Resistance
Tuesday, 10 am - 12 noon
Room: West Hall B

10:00 am 87	Next Generation of Inhibitors of HIV-1 Integrase Strand Transfer Inhibitor: Structural Diversity and Resistance Profiles John Wai*, T Fisher, M Embrey, M Egbertson, J Vacca, D Hazuda, M Miller, M Witmer, L Gabryelski, and T Lyle Merck Res Labs, West Point, PA, US
10:15 am 88	Structures of HIV-1 Reverse Transcriptase Complexed with NNRTI TMC278: Conformational and Positional Adaptability Overcomes Resistance Mutations Joe D. Bauman*¹, K Das¹, M Baweja¹, A Clark Jr¹, P Boyer², A Shatkin¹, P Lewi³, S Hughes², and E Arnold¹ ¹Ctr for Advanced Biotech and Med, Rutgers Univ, Piscataway, NJ, US; ²NCI-Frederick Cancer Res and Devt Ctr, MD, US; and ³Katholieke Univ, Leuven, Belgium
10:30 am 89	Ternary Complex Formation Compromises the Inhibitory Effects of the RT-associated RNase H Inhibitor b-thujaplicinol Greg Beilhartz*¹, J Beutler², S LeGrice², and M Gotte¹ ¹McGill Univ, Montreal, Canada and ²NCI-Frederick, MD, US
10:45 am 90	3’-Azido-3’-Dideoxythimidine Selects Mutations in the Connection (A371V) and RNase H (Q509L) Domains of Reverse Transcriptase that Increase AZT Resistance in Combination with Thymidine Analog Mutations without Affecting the Rate of AZT Excision on a DNA/DNA Template/Primer Jessica Brehm*, D Koontz, S Zelina, N Sluis-Cremer, and J Mellors Univ of Pittsburgh, PA, US
11:00 am 91	Suppression of Dual-tropic HIV-1 Variants by the CXCR4 Inhibitor AMD3100 Is Associated with Efficiency of CXCR4 Use and Clonal Composition of the Baseline Virus Population Signe Fransen*¹, G Bridger², J Whitcomb¹, J Toma¹, N Parkin¹, C Petropoulos¹, and W Huang¹ ¹Monogram Biosci, South San Francisco, CA, US and ²AnorMED Inc, Langley, Canada
11:15 am 92	Nevirapine-resistant HIV-1 among Mozambican Infants Infected in Utero vs Intra-partum or Early Postpartum M Micek^1,2, M Micek^1,2, A Blanco^1,2, A Blanco^1,2, E Matediane³, L Matunha², I Beck⁴, S Dross⁴, P Montoya^1,2, P Montoya^1,2, L Jamisse⁵, S Gloyd^1,2, S Gloyd^1,2, and Lisa Frenkel*¹ ¹Univ of Washington, Seattle, US; ²Hlth Alliance Intl, Seattle, WA, US; ³Mozambique Ministry of Hlth, Biera; ⁴Children's Hosp, Seattle, WA, US; and ⁵Mozambique Ministry of Hlth, Maputo
11:30 am 93LB	Short-course Zidovudine and Lamivudine or single-dose Nevirapine-containing PMTCT Compromises 12-Month Response to HAART in African Women, Abidjan, Côte d’Ivoire (2003-2006) P Coffie¹, D Ekouevi², M L Chaix³, B Tonwe-Gold⁴, S Toure⁴, I Viho⁴, C Amani-Bosse⁴, V Leroy¹, C ROUZIOUX³, François Dabis*¹, D Ekouevie¹, and MTCT-Plus Initiative of ICAP ¹INSERM 593, Univ Victor Segalen, Bordeaux, France; ²ANRS DITRAME PLUS Project, PACCI Collaboration, Abidjan, Côte d`Ivoire; ³Ctr Hosp Univ Necker, Univ Rene Descartes, Paris, France; and ⁴MTCT-Plus Prgm, ACONDA, Abidjan, Côte d`Ivoire
11:45 am 94	Prevalence of HIV-1 Drug Resistance after Virologic Failure of First HAART Regimen in South Africa: Initial Results of the South Africa Resistance Cohort Study Vincent C. Marconi^1,2, Vincent C. Marconi^1,2, H Sunpath³, Z Lu⁴, M Gordon⁵, K Koranteng⁶, J Hampton³, D Ross⁶, E Losina⁴, B Walker⁴, D Kuritzkes¹, and SARCS Team ¹Brigham and Women's Hosp, Harvard Med Sch, Boston, MA, US; ²Wilford Hall US Air Force Med Ctr, Lackland AFB, TX, US; ³McCords Hosp, Durban, South Africa; ⁴Massachusetts Gen Hosp, Harvard Med Sch, Boston, US; ⁵Inkosi Albert Luthuli, Nelson Mandela Sch of Med, Durban, South Africa; and ⁶St Mary's Hosp, Mariannhill, South Africa